LivaNova to Announce First-Quarter 2026 Results
LivaNova Receives U.S. Food and Drug Administration Premarket Approval for aura6000 System to treat Moderate to Severe Obstructive Sleep Apnea
All You Need to Know About LivaNova (LIVN) Rating Upgrade to Buy [Yahoo! Finance]
A Look At LivaNova (LIVN) Valuation After Earnings Show Growth Guidance And A Swing To Net Loss [Yahoo! Finance]
LivaNova (LIVN) had its price target raised by Barclays PLC from $67.00 to $73.00. They now have an "equal weight" rating on the stock.